- Home
- COEP vs GDTC Comparison
COEP vs GDTC Comparison
Compare COEP & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- GDTC
- Stock Information
- Founded
- COEP 2017
- GDTC 2018
- Country
- COEP United States
- GDTC Singapore
- Employees
- COEP N/A
- GDTC N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- GDTC Health Care
- Exchange
- COEP Nasdaq
- GDTC Nasdaq
- Market Cap
- COEP 27.4M
- GDTC 28.0M
- IPO Year
- COEP N/A
- GDTC 2023
- Fundamental
- Price
- COEP $9.65
- GDTC $2.12
- Analyst Decision
- COEP
- GDTC Buy
- Analyst Count
- COEP 0
- GDTC 1
- Target Price
- COEP N/A
- GDTC $5.00
- AVG Volume (30 Days)
- COEP 37.4K
- GDTC 6.6K
- Earning Date
- COEP 08-15-2025
- GDTC 01-01-0001
- Dividend Yield
- COEP N/A
- GDTC N/A
- EPS Growth
- COEP N/A
- GDTC N/A
- EPS
- COEP N/A
- GDTC N/A
- Revenue
- COEP $62,874.00
- GDTC $368,838.00
- Revenue This Year
- COEP N/A
- GDTC $5.37
- Revenue Next Year
- COEP N/A
- GDTC N/A
- P/E Ratio
- COEP N/A
- GDTC N/A
- Revenue Growth
- COEP N/A
- GDTC N/A
- 52 Week Low
- COEP $2.31
- GDTC $1.20
- 52 Week High
- COEP $13.70
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- COEP 62.24
- GDTC 44.40
- Support Level
- COEP $7.25
- GDTC $2.09
- Resistance Level
- COEP $9.90
- GDTC $2.35
- Average True Range (ATR)
- COEP 0.63
- GDTC 0.09
- MACD
- COEP 0.26
- GDTC -0.01
- Stochastic Oscillator
- COEP 85.62
- GDTC 17.54
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.